Sideroblastic anemia secondary prevention
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Shyam Patel [2] Associate Editor(s)-in-Chief: Nazia Fuad M.D.
Overview
Overview
Effective measures for the secondary prevention of sideroblastic anemia include iron chelators, Phlebotomy, regular liver function tests to assess for liver disease. Other measures include regular CBC in patients with MDS, cardiac monitoring, monitoring iron studies , and keeping ferriten level < 500 ng/ml.
Secondary Prevention
Secondary Prevention
Effective measures for the secondary prevention of sideroblastic anemia include:[1]
- Iron chelators
- Phlebotomy
- Regular liver function tests to assess for liver disease
- Regular CBC in patients with MDS myelodysplastic syndrome
- Cardiac monitoring
- Monitor iron studies , keep ferriten level < 500 ng/ml
- Pyridoxine supplementation, 50-100mg a day
References
References
- ↑ Ohba R, Furuyama K, Yoshida K, Fujiwara T, Fukuhara N, Onishi Y; et al. (2013). “Clinical and genetic characteristics of congenital sideroblastic anemia: comparison with myelodysplastic syndrome with ring sideroblast (MDS-RS)”. Ann Hematol. 92 (1): 1–9. doi:10.1007/s00277-012-1564-5. PMC 3536986. PMID 22983749.
Looking for the patient version?
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH